Partial response in two ASPS patient to sorafenib

[Olga]

The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with off-label targeted therapy drugs. Off label means that the drug is approved for other diseases but based on its mode of action it is expected to be beneficial in sarcoma patients who have no other treatment options, prescribed by the treating oncologist. They found that from 5 patients with alveolar soft parts sarcoma that were treated with with sorafenib 2 patients were responders and their tumors shrunk more than 20%. There is a free PDF text avail., but I could not find an info re. how durable the response was - i.e. how long did it last. But anyways it could be used to make a resection easier or possible, create a window of opportunity for other local interventions - ablations, radiosurgery, resection.

The off-label use of targeted therapies in sarcomas: the OUTC'S program.
http://www.ncbi.nlm.nih.gov/pubmed/25420707